scholarly journals Role and Importance of Chlamydia Trachomatis in Pregnant Patients

2016 ◽  
Vol 4 (3) ◽  
pp. 410-412 ◽  
Author(s):  
Mariya Angelova Angelova ◽  
Emil Kovachev ◽  
Veselina Tsankova ◽  
Iliana Koleva ◽  
Silvia Mangarova

AIM: The aim of this study was to assess the prevalence of chlamydial infection among pregnant women and to determine the role of this infection in the fetus.MATERIAL AND METHODS: In the first phase of this study were reported 58 pregnant women with a positive test for active chlamydial infection by applying immunofluorescence. In the second phase of the study were reported pregnant with premature burst membranes (PBM), postnatal complications associated with chlamydial infection as puerperal endometritis, and newborns are monitored for low birth weight and growth retardation at birth.RESULTS: With a positive test are 58 patients in the first trimester or pregnancy registration in our consultation. After regimen with Sumamed (2 x 500 mg for three days and after 10 days again same scheme for them and their partner) at the beginning of the third trimester, the PCR test was made again. Of these, 5 were positive again, participants are between 20 and 30 years old. With premature rupture of OM are 20 patients. There was no increased incidence of premature births. Infants born to infected mothers have a higher risk of developing respiratory symptoms in the first 60 days of life. 3 of them have low for his age bodyweight.CONCLUSIONS: The scarcity of data on manifestations of chlamydial infection during pregnancy and neonatal outcomes justifies this study. Early diagnosis for registration of pregnancy and timely treatment of chlamydial infection as well as scrutinising the infection during the third trimester of pregnancy can prevent infection of the newborn. Therefore, preventive examinations should be considered as a priority for early detection of asymptomatic chlamydial infection in the conduct of antenatal care.

2021 ◽  
pp. 1-1
Author(s):  
Aleksandra Dimitrijevic ◽  
Jovana Bradic ◽  
Vladimir Zivkovic ◽  
Aleksandra Dimitrijevic ◽  
Mirjana Milojevic-Corbic ◽  
...  

Background/Aim. Considering the fact that role of oxidative stress in pathogenesis of thrombophilia in pregnancy has still not been clarified, the aim of our study was to assess the redox status of pregnant women with thrombophilia. Methods. The study involved 120 pregnant women who were divided into two groups: thrombophilia and normal pregnancy group. The thrombophilia group consisted of 60 pregnant women with thrombophilia, while the normal pregnancy group included 60 physiologically healthy pregnant women. Blood samples for biochemical analysis were collected at the end of first, second and third trimester of pregnancy. Concentrations of hydrogen peroxide (H2O2), nitrites (NO2-) and index of lipid peroxidation measured as TBARS were measured in plasma. Level of reduced glutathione (GSH), activities of superoxide dismutase (SOD) and catalase (CAT) were measured in erythrocytes. Results. In women with thrombophilia, NO2- values were increased in the first and third trimester when compared with healthy pregnant women (p<0.05). The higher levels of TBARS and H2O2 were noticed in women with thrombophilia in the first trimester when compared to healthy pregnant women (p<0.05). The values of SOD and CAT were lower in women with thrombophilia in the third and GSH in the first trimester compared to control group (p<0.05). Conclusion. Our results suggest increased generation of pro-oxidants in thrombophillia at the beginning of gestation, which declines as gestation progresses and reaches the similar values as in normal pregnancy at the end of pregnancy. Generally viewed, thrombophilia was associated with impaired antioxidant capacity - SOD and CAT were lower in the third and GSH in the first trimester compared to healthy women.


Author(s):  
Süleyman Akarsu ◽  
Filiz Akbiyik ◽  
Eda Karaismailoglu ◽  
Zeliha Gunnur Dikmen

AbstractThyroid function tests are frequently assessed during pregnancy to evaluate thyroid dysfunction or to monitor pre-existing thyroid disease. However, using non-pregnant reference intervals can lead to misclassification. International guidelines recommended that institutions should calculate their own pregnancy-specific reference intervals for free thyroxine (FT4), free triiodothyronine (FT3) and thyroid-stimulating hormone (TSH). The objective of this study is to establish gestation-specific reference intervals (GRIs) for thyroid function tests in pregnant Turkish women and to compare these with the age-matched non-pregnant women.Serum samples were collected from 220 non-pregnant women (age: 18–48), and 2460 pregnant women (age: 18–45) with 945 (39%) in the first trimester, 1120 (45%) in the second trimester, and 395 (16%) in the third trimester. TSH, FT4 and FT3 were measured using the Abbott Architect i2000SR analyzer.GRIs of TSH, FT4 and FT3 for first trimester pregnancies were 0.49–2.33 mIU/L, 10.30–18.11 pmol/L and 3.80–5.81 pmol/L, respectively. GRIs for second trimester pregnancies were 0.51–3.44 mIU/L, 10.30–18.15 pmol/L and 3.69–5.90 pmol/L. GRIs for third trimester pregnancies were 0.58–4.31 mIU/L, 10.30–17.89 pmol/L and 3.67–5.81 pmol/L. GRIs for TSH, FT4 and FT3 were different from non-pregnant normal reference intervals.TSH levels showed an increasing trend from the first trimester to the third trimester, whereas both FT4 and FT3 levels were uniform throughout gestation. GRIs may help in the diagnosis and appropriate management of thyroid dysfunction during pregnancy which will prevent both maternal and fetal complications.


Author(s):  
Masoomeh Shirzaiy ◽  
Zohreh Dalirsani

Abstract Objectives During pregnancy, systemic physiological alterations lead to some changes in the oral cavity, which could prepare the mouth environment for oral and dental problems. This study was aimed to investigate salivary α-amylase, sialic acid levels, and pH levels in pregnant and nonpregnant females. Materials and Methods In this analytical, case–control study, unstimulated saliva samples were collected with spiting method from 35 pregnant women (case group) and 35 nonpregnant women (control group) and transferred to the laboratory to assess salivary α-amylase, sialic acid, and pH levels. Data were analyzed by SPSS (version: 19) software through statistical methods of independent t-test and analysis of variance. Results The mean sialic acid levels were 2.285 ± 1.230 mg/dL in pregnant and 2.744 ± 1.326 in nonpregnant women without any significant difference (p = 0.138). The mean salivary α-amylase concentrations were 2.461 ± 1.869 U/L and 2.439 ± 2.058 U/L, respectively, in pregnant and nonpregnant women, with no significant difference (p = 0.963).The mean salivary pH in nonpregnant women was significantly more than that in pregnant women (7.845 ± 0.430 and 6.868 ± 0.413, respectively) (p < 0.001). Also, the mean salivary pH levels in pregnant women were 7.474 ± 0.420 in the first trimester, 6.868 ± 0.413 in the second trimester, and 6.568 ± 0.387 in the third trimester, which were significantly different (p < 0.001). Conclusion Salivary sialic acid and α-amylase levels among pregnant women were no different from those of other subjects. During pregnancy, the salivary pH significantly reduced, and the mean salivary pH during pregnancy had a decreasing trend from the first trimester to the third trimester.


2020 ◽  
Author(s):  
Zhengyuan Wang ◽  
Yiwen Wu ◽  
Zehuan Shi ◽  
Jun Song ◽  
Guoquan Wang ◽  
...  

Abstract Background: China’s universal salt-iodization program has all but eliminated iodine deficiency disorders. Concern has shifted to mild iodine deficiency. Our study examined factors with the potential to predict mild iodine deficiency in pregnant women. Methods: A total of 2 400 pregnant women were enrolled using a multistage, stratified, random-sampling method. Data were collected through face-to-face interviews, a standardized questionnaire, an iodine-related knowledge questionnaire, urine samples, and household cooking salt samples. Results: The median urinary iodine concentration (MUIC) was 148.0 μg/L for all participants, and 155.0 μg/L, 151.0 μg/L, and 139.6 μg/L in the first, second, and third trimesters, respectively. The third trimester’s MUIC was significantly lower than that of the first trimester, and the usage rates of iodized salt and qualified-iodized salt were 71.5% and 59.4%, respectively. Iodine-related knowledge was significantly different between the high and low UIC groups. Participants’ MUIC increased significantly with increases in iodine-related knowledge. The third trimester was a significant risk factor for high UIC, whereas abundant iodine-related knowledge, study the dietary knowledge urgently, and consumption of iodine-rich food within 48 hours of a urine iodine test were significant protective factors for high UIC (P<0.05). Conclusions: Iodine levels are adequate among pregnant women in Shanghai during the first and second trimesters, but insufficient in the third trimester. The use of iodized cooking salt does not determine the iodine status of pregnant women. Abundant iodine-related knowledge is important for pregnant women in the third trimester to maintain adequate urinary iodine.


2021 ◽  
Vol 70 (4) ◽  
pp. 43-56
Author(s):  
Roman V. Kapustin ◽  
Elizaveta M. Tcybuk ◽  
Sergey V. Chepanov ◽  
Elena N. Alekseenkova ◽  
Ekaterina V. Kopteeva ◽  
...  

AIM: The aim of this study was to evaluate soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) levels in the blood of women with various types of diabetes mellitus, depending on the correction method applied, and to determine the prognostic significance of the sFlt-1 / PlGF ratio for predicting the development of preeclampsia in this patient population. MATERIALS AND METHODS: We examined 140 pregnant women who were included in six main study groups: type 1 diabetes mellitus (with or without pregravid preparation), type 2 diabetes mellitus (diet therapy or insulin therapy), and gestational diabetes mellitus (diet therapy or insulin therapy). The comparison groups consisted of pregnant women with preeclampsia and patients without complications of pregnancy. Using electrochemiluminescence analysis, PlGF and sFlt-1 levels in the blood serum were determined twice, at 11+013+6 and 30+033+6 weeks of gestation. Statistical data processing was performed using the IBM SPSS Statistics version 23 and GraphPad Prism version 8.0 software packages. RESULTS: In the blood serum of pregnant women with diabetes mellitus in the first and third trimesters of pregnancy, we found an increase in sFlt-1 level and a decrease in PlGF level, as well as an increase in the sFlt-1 / PlGF ratio. These changes were most pronounced in individuals with type 1 diabetes mellitus without pregravid preparation and with type 2 diabetes mellitus on insulin therapy. In patients with pregestational types of diabetes mellitus, the sFlt-1 / PlGF ratio was a predictor of preeclampsia already in the early stages of pregnancy. Analysis of the ROC curve showed that the threshold sFlt-1 / PlGF ratio for predicting preeclampsia in pregnant women with diabetes mellitus in the first trimester was 32.5 (sensitivity 92.9%, specificity 50.0%) and in the third trimester 71.8 (sensitivity 85.7%, specificity 82.3%) with AUC 0.78 (95% CI 0.680.88) and 0.89 (95% CI 0.830.95), respectively. In the first trimester, the positive and negative predictive values of the sFlt-1 / PlGF ratio as a predictor of preeclampsia in pregnant women with diabetes mellitus were 63.3% and 97.6%, respectively; in the third trimester, 38.9% and 93.6%, respectively. CONCLUSIONS: Blood level alterations of PlGF and sFlt-1 are characteristic of patients with diabetes mellitus in the first and third trimesters of pregnancy. An increase in the sFlt-1 / PlGF ratio is associated with a higher incidence of unfavorable perinatal outcomes in women with impaired carbohydrate metabolism. Determination of the sFlt-1 / PlGF ratio is a valid method for predicting the development or absence of preeclampsia in women with diabetes mellitus.


PEDIATRICS ◽  
1979 ◽  
Vol 64 (5) ◽  
pp. 775-780
Author(s):  
Harvey R. Colten ◽  
Gabriel Goldberger

The capacity for complement biosynthesis appears early in gestation. In most species, functional complement and properdin systems are intact by the end of the first trimester. An increase in fetal serum complement concentration (several components) occurs early in the third trimester reaching 30 to 50% of adult levels. The mechanisms for initiation of fetal biosynthesis of complement and the apparent change in rate of synthesis are knknown. The role of complement, if any, in utero is also not known. These will most certainly be subjectics of further investigations.


1997 ◽  
Vol 152 (2) ◽  
pp. 167-174 ◽  
Author(s):  
T K Woodruff ◽  
P Sluss ◽  
E Wang ◽  
I Janssen ◽  
M S Mersol-Barg

Abstract Activin A (βA–βA) and activin B (βB–βB) are related dimeric proteins that regulate numerous cellular activities. Activin activity is bioneutralized by follistatin, a specific and high-affinity binding protein. Recently, our group developed specific and sensitive enzyme-linked immunosorbent activin assays that do not detect either activin isoform when bound to follistatin, therefore, the assays are specific for biologically relevant ligands. Activin A is measurable in the serum of pregnant women (cross-sectional sample collection), while activin B is not detected in maternal serum. However, activin B is measurable in amniotic fluid and cord blood sera. The purpose of this study was to measure serum activin A, activin B, and follistatin prospectively in longitudinally collected samples during pregnancy. This study design offered observations of relative changes in serum hormone concentration with each person serving as an internal reference. Serum samples were collected bimonthly from seven pregnant women beginning within the second month of gestation, and up to, but not including, the onset of labor. Six of the seven women had normal labor and delivery. One patient required pitocin (an oxytocin agonist) for induction of labor which led to delivery. Activin A, activin B, total follistatin, free follistatin, human chorionic gonadotropin, estradiol, progesterone, FSH, and LH were measured in maternal serum samples using specific assays. Serum activin A levels increased in the final month of pregnancy in the six patients who delivered following normal labor (<0·78 ng/ml (first trimester) to 1–6 ng/ml (term)). Activin B was not detected in any serum sample (<0·78 pg/ml). Total serum follistatin (free follistatin, follistatin–activin, and follistatin–inhibin) increased 10- to 45-fold in the final month of pregnancy in four of the women undergoing normal labor (10 ng/ml (first trimester) to 100–450 ng/ml (final month)). Total follistatin was high and variable in two women throughout pregnancy. Total follistatin returned to basal serum concentration in three of the patients during the last 2 weeks of pregnancy. Free follistatin was detected throughout pregnancy (range <2–35 ng/ml). Free follistatin represented a small percentage of the total follistatin throughout the time of pregnancy and did not rise coincident with the rise in total follistatin. Serum activin A and activin B were not detected during the entire course of pregnancy in the one patient who did not have normal labor and total follistatin did not rise in the last trimester of pregnancy. Gonadotropin and steroid hormones were measured in all patients and were within normative ranges for human pregnancy (inclusive of the non-laboring patient). The results suggest that immunodetectable activin A is present in the third trimester of pregnant women who have normal onset labor. The total follistatin assay results suggest that follistatin–activin (or –inhibin) complexes are upregulated during the third trimester of pregnancy. Importantly, activin A production exceeds the binding capacity of circulating follistatin. Because binding protein free activin A is biologically active we conclude that the activin A detected in late pregnancy is biologically relevant. The findings are consistent with our hypothesis that activin A is an endocrine factor during the last trimester of human pregnancy and may be involved in normal labor. Journal of Endocrinology (1997) 152, 167–174


2019 ◽  
Vol 13 (4) ◽  
pp. 26-35
Author(s):  
O. A. Krichevskaya ◽  
Z. M. Gandaloeva ◽  
A. B. Demina ◽  
S. I. Glukhova ◽  
T. V. Dubinina

Inflammatory rhythm back pain and enthesitis are one of the main clinical manifestations of ankylosing spondylitis (AS), which increase in severity during pregnancy. However, addition of back pain and, possibly, enthesis in the second half of gestation, which is associated with normal pregnancy, needs to make a differential diagnosis for clarifying the genesis of pain and choosing the right management tactics, which determines the relevance of this study.Objective: to investigate the course of pain in the back, enthesis, and inguinal region, as well as the functional status in AS patients during pregnancy and to reveal clinical signs that most accurately reflect inflammatory activity during gestation.Patients and methods. A study included 36 pregnant women with a reliable diagnosis of AS according to the modified New York criteria (1984). Their mean age was 31.6±4.8 years, the mean age at the onset of AS was 21.8±10.9 years; the duration of the disease was 134.9±89.3 months. A control group comprised 30 healthy pregnant women with no history of back pain and arthritis; their mean age was 28.2±4.5 years. The pregnant women of both groups were matched for parity. They made visits at 10–11, 20–21, and 31–32 weeks of pregnancy. Pain intensity was estimated using the numerical pain rating scale (NPRS) and the functional status was assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI). The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) was used to assess enthesitis.Results and discussion. During pregnancy, 94% of AS patients had back pain; its intensity by trimesters was 3 [2; 4], 4 [3; 5.5], 3 [2; 7] and was higher than in healthy pregnant women (p<0.0001). In the study group, there was a rise in pain intensity at night with increasing gestational age (n=23–28): 2 [1; 4] in the first trimester; 3 [0; 5] II in the second trimester; 3 [1; 6] in the third trimester (p< when comparing the first, second, and third trimesters) and an increase in the duration of morning stiffness (n= ): 10 [5; 20], 15 [10; 55], and 15 [5; 60] min, respectively. Moreover, the number of women who reported improvements after exercise (85–63%) and no improvement at rest (88–56%) declined (p<0.05 when comparing the first, second, and third trimesters).In the control group, 1 and 3 patients had morning back stiffness and night pain, respectively. The healthy pregnant women more frequently reported a reduction in back pain after exercise in the third trimester (66.7% of those with pain) than in the first trimester (20% of those with pain) (p<0.05).By the third trimester, the patients with AS showed a change in the nature of back pain: 43.7% of the patients reported an improvement at rest; 42.4% noted an increase in pain after exercise, while the frequency of elements of mechanical back pain was less than that in the control group (p < 0.05).The intensity of groin pain (2.4±1.9, 3.3±2.4, and 4.3±3.0 in the first, second, and third trimesters, respectively) did not differ in AS patients with and without coxitis or pelvic enthesitis. The frequency of enthesitis and MASES scores in the study group were higher than in the control group (p<0.05), the MASES scores increased with gestational age, amounting to 0 [0; 1] in the first trimester and 2 [0; 3] in the third trimester (p<0.05).Functional disorders during pregnancy increased in both groups; there was a difference in BASFI scores between the groups only in the third trimester: 3.5±2.8 and 1.7±1.2, respectively (p<0.05).Conclusion. Back pain and functional disorders increase in AS patients during gestation. Night back pain, morning stiffness, and enthesitis reflect the inflammatory activity of AS during pregnancy. Mechanical back pain joins in 40% of women with AS in the third trimester. The criteria for inflammatory back pain and BASFI require adaptation when used in pregnant women.


2020 ◽  
pp. 60-68
Author(s):  
E. O. Bamisaye ◽  
M. A. Okungbowa ◽  
D. T. Alade ◽  
O. Brown- West ◽  
G. T. Oluwasuji

Aim: This study evaluated D-dimer level in pregnant and non-pregnant women in Southwestern Nigeria in order to provide more information on the concentration and liable risks in this region. Study Design: This is a cross sectional study where convenience sampling method was applied in sample collection. Place and Duration of Study: Blood samples were collected from pregnant women             attending the antenatal clinics of Federal Teaching Hospital Ido-Ekiti (FETHI), Ekiti; Federal                Medical Centre (FMC), Owo; and LAUTECH Teaching Hospital (LTH), Osogbo in Southwestern Nigeria. Methodology: Exactly three hundred pregnant (300) and one hundred and fifty (150) apparently healthy non pregnant women were recruited for this study. The blood samples were analysed for haematocrit (HCT) and platelet count using Sysmex KX-2IN (Japan); prothrombin time (PT) and activated partial thromboplastin time (APTT) by Diagen reagents (Diagnostic Ltd., UK); the international normalized ratio (INR) was calculated from the PT results; and D-dimer quantitative assay using Tina Quant Gen 2 on Cobas C111 (Roche). Data analysis was performed using IBM-SPSS version 25.0; mean and standard deviation was used to summarize continuous variables and descriptive and Inferential statistical tests were employed with level of statistical significance was determined at p<0.05. Results: The mean D-dimer levels were significantly higher in the pregnant women (0.87 ± 1.00 ugFEU/ml) than in controls (0.31 ± 0.22 ugFEU/ml) with 42% of the pregnant population having elevated concentration while the mean PT, INR and HCT were significantly higher in controls than the subjects (p<0.05).Furthermore, the HCT, platelet, PT and INR were observed to be highest at first trimester; 36.04±5.09 (L/L), 182.72±35.11 (x109/L), 11.80±1.86 (seconds) and 0.35±0.15 respectively, decreasing across the second and the third trimester. On the other hand, the D-dimer and APTT increased exponentially from the first trimester; 0.42±0.18 (ugFEU/ml) and 30.80±3.30 (seconds), through the second and third trimesters respectively (p>0.05). Conclusion: This study shows a significant increase in D-dimer in the pregnant subjects when compared with the control and an exponential increase in the third trimester, also a significant reduction in some other baseline coagulation profile hence depicting D-dimer as a notable significant marker of coagulation and fibrinolysis. This therefore emphasizes the hypercoagulable state of pregnancy and a need for adequate monitoring.


2015 ◽  
Vol 125 (4) ◽  
pp. 197-200
Author(s):  
Anna Cisek ◽  
Marzena Bucholc

Abstract Introduction. It is estimated that 90% of pregnant women suffer from nausea and vomiting (NVP). The severity of NVP may vary and the first symptoms tend to appear between the 4th and 9th week of pregnancy, reaching their peak around 7th-12th week and disappear around 16th-20th week of pregnancy. The etiology of both nausea and vomiting is yet to be discovered, yet there is a number of factors that may contribute to it. These symptoms usually accompany the increase of human chorionic gonadotropin (hCG) and most intensive ailments associated to the highest rate of this hormone appear around the 10th week of pregnancy. Aim. Assessing the severity of nausea and vomiting in pregnant women and selected risk factors. Material and methods. The study group consisted of 150 women hospitalized in the Independent Public Teaching Hospital No 4 in Lublin. The head of the Department of Obstetrics and Perinatology Agreement has agreed for the studies to be conducted. The authors used a research tool named modified scale Pregnancy Unique Quantification of Emesis which allowed to investigate the incidence and severity of nausea and vomiting during pregnancy. Demographic data and information on the conditions of nausea and vomiting in pregnancy were collected using a questionnaire survey of the authors’ own making. Database and statistical tests were conducted using 10.0 STATISTICA software (StatSoft, Poland). Results. The analysis revealed that 108 women (72.00%) experienced nausea or vomitting during pregnancy. Taking into consideration the first trimester of pregnancy, a moderate severity of nausea and vomiting (NVP) occurred with an average of 6.51±3.17 pt. It was found that 82 respondents had light intensity of NVP, whereas 68 moderate. In the second trimester an average intensity of nausea and vomiting (NVP) came to 4.82±2.45 pt, i.e. 117 women had mild symptoms while 33 had moderate symptoms. During the third trimester NVP severity dropped to 3.88±1.67. The majority of respondents stated that nausea and vomiting was of light intensity (92.00%), while 8% declared that it was moderate. Conclusions. The severity of nausea and/or vomiting varies in the course of pregnancy, with significantly more moderate than mild symptoms occurring in the first compared to other trimesters of gestation. The degree of the severity of NVP in the third trimester of pregnancy is significantly affected by risk factors occurring before pregnancy (migraine headache, nausea or vomiting), and co-morbidities. However, the number of pregnancies, the fact whether the pregnancy was planned or not, motion sickness do not have major significance in this matter.


Sign in / Sign up

Export Citation Format

Share Document